Abstract
Children with cancer receiving immunosuppressive therapy are vulnerable to severe pneumococcal disease (IPD). This thesis examines the role of the 13-valent pneumococcal conjugate vaccine (PCV13) in children undergoing (AIT) or recently completed immunosuppressive cancer therapy (CIT) to prevent and reduce IPD. A prospective, open-label cohort study included children with cancer given a dose of PCV13 demonstrated satisfactory immunogenic responses and low rate of serious adverse events. Our study design was suboptimal to evaluate vaccination and its role for preventing nasopharyngeal colonization.
Original language | English |
---|---|
Qualification | Masters |
Awarding Institution |
|
Supervisors/Advisors |
|
Award date | 28 Aug 2018 |
DOIs | |
Publication status | Unpublished - 2018 |